Clinical Trial Update: hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of the hu14.18-Interleukin-2 fusion protein in young patients with recurrent or refractory neuroblastoma has completed enrollment and posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• hu14.18-Interleukin-2 fusion protein (hu14.18-IL-2)

Snippet

Sponsor: Children's Oncology Group | Conditions: Neuroblastoma | Phase 2 | Status: COMPLETED | Results posted: 2014-01-16